The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

By D. Arber, A. Orazi, R. Hasserjian, J. Thiele, M. Borowitz, M. L. Le Beau, C. Bloomfield, M. Cazzola, J. Vardiman. Blood, 2016

8,916 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia (2020, background): “Currently, diagnosis rests on the percentage of blasts (20% or 30%) in blood or marrow [6, 94].”
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer (2023, methodology): “The European Society of Rheumatology (EULAR) in 2019 equated the application of JAK inhibitors with that of biological DMARDs (bDMARDs) in circumstances where conventional synthetic DMARDs (csDMARDs) are ineffective.192–194 A large observational study of the efficacy of commonly used second-line RA ”
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. (2017, background): “Eight balanced translocations and inversions, and their variants, are included in the WHO category “AML with recurrent genetic abnormalities”.(3,4) Nine balanced rearrangements and multiple unbalanced abnormalities are sufficient to establish the WHO diagnosis of “AML with”